GlaxoSmithKline: Diabetes Mellitus trials
The registry lists 38 Diabetes Mellitus studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 19 have results posted.
Phase 1 10Phase 2 10Phase 3 11Phase 4 3No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic PainTerminatedNCT05838755Phase 2Results posted
- A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy SubjectsTerminatedNCT02802514Phase 4Results posted
- Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes MellitusCompletedNCT02465515Phase 4Results posted
- Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus PatientsCompletedNCT02000817Phase 1/2Results posted
- Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking MetforminCompletedNCT01929863Phase 2Results posted
- A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes MellitusCompletedNCT01777282Phase 3Results posted
- To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 DiabetesCompletedNCT01725126Phase 2Results posted
- Cancer in Patients With Gabapentin (GPRD)CompletedNCT01236053Results posted
- Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)CompletedNCT01138124Results posted
- Safety and Efficacy of Albiglutide in Type 2 DiabetesCompletedNCT00849056Phase 3Results posted
- Safety and Efficacy Study of Albiglutide in Type 2 DiabetesCompletedNCT00849017Phase 3Results posted
- A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 DiabetesCompletedNCT00839527Phase 3Results posted
- A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 DiabetesCompletedNCT00838916Phase 3Results posted
- Efficacy and Safety of Albiglutide in Treatment of Type 2 DiabetesCompletedNCT00838903Phase 3Results posted
- Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)CompletedNCT00500331Phase 2Results posted
- TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)TerminatedNCT00451321Phase 2Results posted
- A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo StudyCompletedNCT00432679Phase 3Results posted
- RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in DiabetesCompletedNCT00379769Phase 3Results posted
- Study Of GW823093 In Japanese Subjects With Type 2 Diabetes MellitusCompletedNCT00372957Phase 2Results posted
- This Study Aims to Determine the Incidence, of Hepatitis B Diagnosis Among Diabetes Mellitus Patients of 0-80 Years of AgeCompletedNCT02324218
- Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health VolunteersTerminatedNCT01725672Phase 1
- Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DMCompletedNCT01648153Phase 2
- WEUKBRE5716: Steroid-related Damage in Systemic Lupus Erythematosus (Hopkins)CompletedNCT01616472
- Use of Beta-blockers and Risk of New Onset DiabetesCompletedNCT01587638
- A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes MellitusCompletedNCT01495013Phase 3
- A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing.CompletedNCT00733577Phase 1
- A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or HydrochlorothiazideCompletedNCT00671424Phase 1
- First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050CompletedNCT00607906Phase 1
- A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy AdultsCompletedNCT00532610Phase 1
- A Study Of BRL49653C For The Treatment Of Type 2 DiabetesCompletedNCT00523913Phase 3
- A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of MetforminCompletedNCT00519480Phase 1
- A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy VolunteersCompletedNCT00501930Phase 1
- Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 DiabetesCompletedNCT00376038Phase 1
- GW823093C For The Treatment Of Type 2 Diabetes MellitusTerminatedNCT00370942Phase 2
- Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.CompletedNCT00306696Phase 4
- BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-CompletedNCT00297063Phase 3
- GSK189075, GW869682 Or Placebo In Type 2 Diabetic PatientsCompletedNCT00291356Phase 2
- Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or InsulinCompletedNCT00269061Phase 1